5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.16▼ | 4.12▲ | 4.11▲ | 4.27▼ | 4.71▼ |
MA10 | 4.12▲ | 4.09▲ | 4.24▼ | 4.52▼ | 7.03▼ |
MA20 | 4.09▲ | 4.20▼ | 4.23▼ | 4.90▼ | 4.11▲ |
MA50 | 4.25▼ | 4.27▼ | 4.63▼ | 7.38▼ | 2.40▲ |
MA100 | 4.44▼ | 4.94▼ | 5.28▼ | 4.09▲ | 7.05▼ |
MA200 | 4.99▼ | 7.68▼ | 7.11▼ | 2.62▲ | 766.19▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.017▲ | 0.009▲ | 0.017▲ | 0.014▲ | -0.188▼ |
RSI | 46.977▼ | 46.451▼ | 43.619▼ | 36.295▼ | 50.024▲ |
STOCH | 92.242▲ | 62.242 | 9.140▼ | 36.608 | 10.956▼ |
WILL %R | -22.222▲ | -84.409▼ | -84.409▼ | -73.259 | -84.608▼ |
CCI | 91.877 | -4.477 | -26.996 | -99.480 | -30.139 |
Tuesday, September 09, 2025 06:20 AM
Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg ...
|
Thursday, August 21, 2025 05:15 AM
MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug ...
|
Tuesday, August 19, 2025 06:30 AM
Nuwellis (NASDAQ:NUWE) has signed a non-binding letter of intent to acquire Israeli-based medical device company, Rendiatech. A 45-day due diligence period has commenced. Should both parties agree to ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/09/25 | 4.095 | 4.195 | 4.01 | 4.155 | 185,979 |
15/09/25 | 4.24 | 5.23 | 4.18 | 4.70 | 888,562 |
12/09/25 | 4.19 | 4.219 | 4.1003 | 4.18 | 19,411 |
11/09/25 | 4.01 | 4.35 | 4.01 | 4.21 | 74,779 |
10/09/25 | 4.20 | 4.2687 | 4.0025 | 4.11 | 102,471 |
09/09/25 | 3.98 | 4.42 | 3.7407 | 4.34 | 1,440,776 |
08/09/25 | 4.775 | 4.91 | 4.66 | 4.77 | 33,264 |
05/09/25 | 4.76 | 4.90 | 4.67 | 4.88 | 22,305 |
04/09/25 | 4.82 | 5.0747 | 4.76 | 4.89 | 30,651 |
03/09/25 | 4.94 | 5.06 | 4.83 | 4.925 | 16,958 |
|
|
||||
|
|
||||
|
|